Policy makers in high, low and middle income countries alike face challenging choices about resource allocation in health. Economic evaluation can be useful in providing decision makers with the best evidence of the anticipated benefits of new investments, as well as their expected opportunity costs -the benefits forgone of the options not chosen.
Economic evaluation and good decision making
Good decisions are those that attempt to maximise benefits and minimise harms. Benefits and harms of a health policy decision are often difficult to identify and measure fully, so the evidence base for both is rarely complete. The opportunity costs of a decision -the benefits forgone or harm caused as a result of spending limited resources on one intervention and not on another -are even more elusive. Further, decision-making in health is inherently value-laden; individual and collective beliefs, needs and aspirations commonly influence spending priorities.
To make good decisions, decision-makers -whether they are local or national policy makers, clinicians, institutions, non-government organisations, or global funding bodiesnot only need sound evidence of the likely costs, benefits and opportunity costs of their choices, but they have to filter the evidence through a prism of values, whether their own, those of the agency for which they work, of a particular stakeholder group, or of society in general.
When used in health, "economic evaluation" refers to a suite of methods for identifying the costs and benefits expected from a health intervention, such as an individual technology or clinical intervention, a platform for a variety of interventions, public health programmes, or a wider service development (Culyer 2014) . Economic evaluation can play an important part in clarifying the likely consequences of a decision (including the opportunity costs) thereby enhancing the quality of decision-making . care resources. This paper presents a summary of the International Decision Support Initiative (iDSI) Reference Case (iDSI 2015a), which aims to improve the usefulness of information produced through economic evaluation thereby contributing to good decision making globally.
What is a reference case for economic evaluation?
A reference case guides the planning, conduct and reporting of economic evaluation so that both the approach to the analysis and the presentation of the results are coherent, transparent and consistent. But more than this, a reference case goes beyond recommendations of good practice methodology and analytics and constitutes an explicit position statement on a range of scientific and social values inherent in the practice of economic evaluation. A major motivation for using a reference case is that it enables institutions or individuals wanting to use economic evaluation to inform their decisions to do so in full knowledge of its limitations and relevance to the decision problem at hand.
In 1996 the US Panel on Cost-Effectiveness in Health and Medicine first proposed the use of a reference case as a means of improving quality and comparability in conduct and reporting cost effectiveness analyses (Gold 1996 does not compare the intervention in question with all the options feasibly available to the intended decision maker, the analysis may not accurately reflect the decision problem and fail fully to enumerate the relevant costs, benefits and opportunity costs. The decision maker may understandably reject the analysis as an input to the decision process, or worse, incorporate it and make an ill-informed and potentially sub-optimal choice.
Economic evaluations that are not conducted and reported systematically and clearly with a minimum standard of methodological quality have limited transferability (Drummond 2009a) . The transferability of an economic evaluation indicates its applicability to different contexts and decisions, and improves the value of an economic evaluation by enabling it to inform decisions beyond the context for which it was conducted. Transferability becomes increasingly important in resource-constrained settings where the substantial human and financial resources required to conduct an economic evaluation constrain its routine use in decision making.
Developing and using a reference case to guide the conduct and reporting of economic evaluation of a variety of technologies including interventions and services, programmes and delivery platforms is, therefore, a potential way to consistently improve methodological quality and transferability, and to make the necessary value judgements involved in conducting and using an economic evaluation more transparent.
However, there is a trade-off between conducting an economic evaluation that can provide useful information for different places and contexts and one that is also sufficiently specific to reflect actual, invariably local, decision problems (Sculpher 2004 , Murray 2000 . In addition, promoting consistency in economic evaluation should be weighed against imposing prescriptive methodological rules on researchers that may constrain the use of methods best suited to the decision problem in light of analytical constraints. When the identity of the decision maker and the population to be affected by the decision remains constant (as with NICE for decisions affecting only the NHS in England), transferability and researcher discretion become less crucial and a relatively prescriptive reference case may be applied. However, these trade-offs become a key consideration if a reference case is to be applied to economic evaluations intended to inform multiple decision makers, populations and contexts.
The case for the iDSI Reference Case
The national-level standardisation of methods adopted by NICE in England has also been implemented elsewhere; to date, mandatory or recommended standards or guidelines for economic evaluation are available in more than 30 countries (Eldessouki 2012 The iDSI Reference Case has been developed to respond to this challenge. It is not intended to provide a definitive reference case or a standard prescriptive set of methods to be used in all economic evaluations globally. Nor is it suggested that, by using a common reference case, all resource allocation decisions should be made in the same way, incorporate the same types of evidence, or weigh different inputs equally. Rather, the iDSI Reference Case seeks to articulate common principles for the generation of evidence, based on the normative assumption that a health policy decision maker seeks information to facilitate decisions that maximise benefits, with a focus on health outcomes.
In this way the iDSI Reference Case does not seek to specify all the information that should inform a decision or assume that decision making in health is devoid of value judgements. Rather, it enables decision makers to apply personal, institutional or political value judgements with knowledge of the likely consequences, including the opportunity costs, of applying these to a common substrate: population health.
There are many excellent publications and resources available on best practices for the planning, conduct, and reporting of economic evaluations (e.g. Gold 1996 , Gray 2010 . The iDSI Reference Case seeks to build on, rather than replicate this knowledge. But beyond being merely a good practice guideline, the iDSI Reference Case articulates a set of principles, with sound decision making rather than academic rigour as the ultimate goal, and asks those undertaking economic evaluations to maintain these principles in the planning, conduct and reporting of their analyses. By avoiding the imposition of specific value judgements and policy parameters, economic evaluations that use the iDSI Reference Case are also encouraged to accommodate the incorporation of local values and parameters into the decision-making process.
The iDSI Reference Case should not be applied inflexibly; rather it should be used to optimize the use of specific methods and existing evidence to produce useful and highquality analyses. Where it is not possible to adhere to particular principles specified in the The development of the iDSI Reference Case
As a major funder of international development in health, the BMGF is obliged to spend money ethically and wisely. Moreover, the BMGF has an interest in sound decisionmaking, the intelligent use of available evidence, and the pursuit of efficiency and equity in health (BMGF, 2015) . To further these aims, BMGF commissioned NICE International to coordinate an initiative aimed at ensuring that BMGF-funded economic evaluations were conducted and reported with consistently high methodological quality, and could thus become a useful input into decision making in LMIC settings (NICE International, 2014a).
As part of this initiative, a review of economic evaluations in LMICs was conducted, looking specifically at those funded by BMGF. The review found that BMGF had funded the highest proportion of economic evaluations in LMICs since the year 2000 in the vaccine, malaria, TB and HIV/AIDS programme areas, but with substantial variation in quality and consistency in both their conduct and reporting. For example, just over a third of the included economic evaluations did not report the time horizon used and half did not explain why particular comparators were chosen for the analysis (Santatiwongchai 2015) .
The review indicated that a reference case tailored to the needs of decision makers in The iDSI Reference Case Structure
The iDSI Reference Case has a structure consisting of principles, methodological specifications, and reporting standards.
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The principles of the iDSI Reference Case inform corresponding methodological specifications, which in turn inform reporting standards. The principles describe the key characteristics of economic evaluations that are fit for purpose, outlining underlying concepts to guide methodological choice, without specifying particular metrics or parameter values. The methodological specifications are a non-exhaustive set of methodological options that are aligned with a corresponding principle. While some methodological specifications represent minimum standards of analytical quality (e.g.
requiring a systematic evidence search to identify key parameters), many are decision and context dependent. This allows some flexibility to ensure that the methods that are appropriate to the decision problem -for example, whether to apply a static or dynamic model in an economic evaluation of an intervention in infectious disease, and how nonbudgetary constraints should be characterised. The structure of the iDSI Reference Case is intended to support three key objectives:
• the routine application of fundamental principles by researchers and decisionmakers in the planning, conduct and reporting of economic evaluation in order to optimize its value in informing good decisions in health;
• the use of methods that adhere to the same fundamental principles to achieve a minimum standard of methodological quality while remaining appropriate to the context and analytical constraints of the decision problem the economic evaluation is intended to inform;
• clear and transparent reporting of economic evaluations to improve their accessibility and usefulness to decision makers and to encourage comparability of both the content and results to different contexts.
A framework for methods development Facilitating capacity-building and technical assistance
The iDSI Reference Case is intended to serve as a global public good, and iDSI and other initiatives will provide a potential framework for both external technical assistance and country-led capacity building initiatives in LMICs. Ethiopia is an example of a country where there is potential for the iDSI Reference Case to be used in this way. Projected to be a middle income country by 2025 (Moller, 2015) , Ethiopia has made significant steps in strengthening its healthcare system in recent years, improving the governance and transparency of its operation and extending coverage to an increasing proportion of its 
Components of the iDSI Reference Case
The eleven principles of the iDSI Reference Case are listed in table 1, and the corresponding methodological specifications are summarised in table 2. The transparency, comparators, constraints and outcome measure principles have generated substantial interest in the development and initial application of the iDSI Reference Case and are described below. A full description of all elements of the iDSI Reference Case, including Reporting Standards, is available on the iDSI website (iDSI 2015a).
Transparency
The transparency principle underpins all other components of the iDSI Reference Case, in particular the Reporting Standards. The need for improvement in the clarity of reporting and alignment of analysis to the stated decision problem in economic evaluations based in LMIC settings was a consistent theme raised by consultees in the reference case development process. Consultees considered that even the most methodologically robust economic evaluation will not be informative if the decision problem, methods and results of the economic evaluation are not reported clearly and transparently. Building on existing reporting frameworks (Husereau 2009 , the transparency principle and corresponding methodological specifications go beyond a requirement for clear reporting.
It also seeks an explicit and consistent link between the stated decision problem and the informational needs of the decision the analysis is intended to inform.
Improved transparency in the conduct and reporting of economic evaluation also aligns with initiatives to address barriers to transferability (Drummond 2009a ). Clear and transparent reporting allows research undertaken in one particular context to be applied to decision-making in another, as even where the overall results of the economic evaluation may not be transferable, aspects of the research may still inform analyses in other contexts. Ultimately, however, the transparency principle underscores the primacy of the role of economic evaluations in informing decisions. Clarity and transparency in an economic evaluation not only enhance the transparency of the decision the analysis seeks to inform, but also the accountability of the decision-maker to the relevant stakeholders.
Comparators
Identifying the comparator against which costs and effects will be measured is critical to ensuring that the analysis both accurately informs the decision problem and is relevant to local decision making.
Comparative incremental analysis against current practice can most accurately reflect the true nature of the decision problem facing local decision makers. The implications of reporting incremental, rather than average costs and effects for an intervention has been well established (Karlsson 1996 . However, a limitation of only comparing an intervention to current practice is that if current practice does not represent an optimal use of resources, the resultant incremental cost effectiveness ratio will not be a good indicator of value for money (Murray 2000 . To address this issue, as a minimum requirement, the iDSI Reference Case requires comparative analysis of therapies currently in routine use (current practice), with additional analysis exploring comparison against best-supportive, non-interventional care in the context of the decision problem. This approach will allow the analysis to accurately reflect the incremental costs and effects of an intervention but will also identify where current practice does not reflect optimal care.
Incorporating the transparency principle, the iDSI Reference Case requires researchers to explain their choice of comparator(s) and how it reflects the decision problem the economic evaluation is intended to inform.
Measure of outcome
The measure of outcome chosen is critical to the scope of the decision that can be informed by an economic evaluation. The iDSI Reference Case is envisioned as a guide for economic evaluations that are intended to inform decision making in health and address issues of equity and efficiency. Although improving health is not the only source of benefit from health care and public health initiatives, it is likely to be the issue of central concern so it is appropriate for health outcomes to be the focus in economic evaluations.
This means that a measure of health outcome is required that is broad enough to capture the most significant and important aspects of health and can be applied consistently to different types of health technology, interventions and programmes across the population.
Where the scope of the decision problem is limited to interventions and comparators that impact either length of life or health-related quality of life, consistently using a measure that captures length and health-related quality of life and is generalizable across disease states allows consideration of opportunity costs for the entire health sector, and facilitates comparisons across investment types. While a disease-specific outcome measure will inform decisions of technical efficiency, it will limit the ability of the decision-maker to make reasoned trade-offs between competing investments in different disease states, and can undermine comparability and consistency in decision-making.
The The benefits and limitations of both the DALY and QALY have been extensively documented (Anand 1997 , Gold 2002 , Lipscomb 2009 , and researchers will need to exercise judgement in choosing the most appropriate measure(s) for a given economic evaluation. Importantly, both the DALY and the QALY are based on a series of assumptions and simplifications which necessitates judgements about the appropriateness of the methods used to quantify health state preferences and the accuracy of the resultant measures. In addition, the use of DALYs and QALYs implicitly incorporates value judgements such as the additivity of health and ability to compare health across populations and conditions. Researchers should be aware of these judgements and assumptions when conducting and reporting analysis.
Depending on the scope of the decision problem however, the most appropriate outcome measure may sometimes be intervention or disease specific, and a generalizable outcome measure may be irrelevant or impractical to calculate. In all cases, a justification of outcome measure chosen is required. Future iterations of the iDSI Reference Case will provide further guidance for researchers on the appropriate choice and calculation of an outcome measure. The fundamental consideration is that the choice of outcome measure is aligned to the needs of the intended decision maker and that the methods used to calculate the outcome measure are comprehensively and transparently described.
Constraints
Economic evaluation seeks to provide evidential and analytic support to decision making regarding resource allocation in a constrained environment. As such, the objective of enhancing the health of the population (and other relevant measures of benefit such as, for example, financial protection) has to be seen against the constraints that apply in the system to achieve these objectives. Various types of constraint exist of which decision makers need to be mindful.
Key constraints relate to resource scarcity, which is an unavoidable reality in all systems, but is most challenging to decision makers in low-income settings. Limits to the financial resources available to a system ('budget constraints') should be reflected in any economic evaluation. This involves providing decision makers with estimates of the scale of additional cost ('budget impact') associated with a new investment. A good analysis will take this further, however, and seek to quantify the opportunity costs associated with a new investment that requires additional financial resources and, as such, diverts those resources away from other activities. Such displacement will inevitably impact on the actual or potential health (and other benefits) accruing to other types of individuals. The nature and magnitude of these opportunity costs should be a key type of evidence informing the decision. In the context of incremental cost-effectiveness analysis, the measure of opportunity costs can be expressed as the threshold that is used to guide (although not to dictate) whether an incremental cost-effectiveness ratio is acceptable to the system. A cost-effectiveness threshold that reflects opportunity costs directly links the cost-effectiveness of a new investment with its affordability . For new interventions that impose a larger impact on limited financial resources, more valuable alternative activities will have to be displaced to fund it, imposing higher opportunity costs -in effect, equivalent to a lower cost-effectiveness threshold. This 'supply side' conceptualization of the cost-effectiveness threshold that reflects the rate at which the system can currently translate additional resources into health (and other) benefits is appropriate to guide decisions about resource allocation given existing financial resources. It contrasts with other conceptualizations of the threshold that have been posited which are more focused on what funding envelope should be devoted to health care (a 'demand side' concept) (Woods and Revill 2016) , (iDSI 2015b), (Culyer 2016) .
Although the implications of the constraints that exist on a system's financial resources are perhaps the most obvious for analysts to present in economic evaluation, the principles remain true for other constraints as well. In low and middle income settings, a particularly important constraint relates to human capital -e.g. limits to the availability of skilled clinical staff to deliver particular services. These limits may reflect not only limits to the financial resources needed to fund more staff, but also may simply reflect the number available, at least in the short-term. With respect to financial constraints, analysts should seek to inform decision makers of the impact of a new investment on the constrained human resource (how many needed versus how many available), and the magnitude of the opportunity costs (in terms of health and other benefits) involved in diverting them from existing activities. As such, the real (opportunity) cost of a constrained resource may be quite different from its apparent financial cost.
Conclusion
The iDSI Reference Case is the first standardised principle-based methodology for the planning, conduct and reporting of economic evaluations of health interventions developed specifically with a LMIC focus.
The iDSI Reference Case stresses the primacy of the needs of decision makers to deliver sound decisions, and its principle-based approach provides the flexibility to enable it to be used in different countries, applied to different technologies and interventions, and in support of a variety of decisions. Crucially, the iDSI Reference Case will support decisions aimed at improving population health from within available funding, while acknowledging the relevance and trade-offs associated with the incorporation of social values into those decisions. Ultimately though, the iDSI Reference Case is only a tool, and can inform, but not replace, the judgement of accountable decision makers. Table 1 The iDSI Reference Case Principles 1 An economic evaluation should be communicated clearly and transparently to enable the decision-maker(s) to interpret the methods and results.
2 The comparator(s) against which costs and effects are measured should accurately reflect the decision problem.
3 An economic evaluation should consider all available evidence relevant to the decision problem.
4
The measure of health outcome should be appropriate to the decision problem, should capture positive and negative effects on length of life and quality of life, and should be generalizable across disease states.
5
All differences between the intervention and the comparator in expected resource use and costs of delivery to the target population(s) should be incorporated into the evaluation.
6
The time horizon used in an economic evaluation should be of sufficient length to capture all costs and effects relevant to the decision problem; an appropriate discount rate should be used to discount cost and effects to present values.
7
Non-health effects and costs associated with gaining or providing access to health interventions that don't accrue to the health budget should be identified where relevant to the decision problem. All costs and effects should be disaggregated, either by sector of the economy or to whom they accrue.
8
The cost and effects of the intervention on sub-populations within the decision problem should be explored and the implications appropriately characterised.
9
The uncertainty associated with an economic evaluation should be appropriately characterised.
10
The impact of implementing the intervention on the health budget and on other constraints should be identified clearly and separately.
11
An economic evaluation should explore the equity implications of implementing the intervention. • Apply a systematic and transparent approach to obtaining evidence and to judgments about evidence exclusion • Estimates of clinical effect of intervention and comparator(s) should be informed systematic review of the literature • Single-study or trial-based analyses should outline how these are an adequate source of evidence and should ensure that the stated decision problem is specific to particular context and time of the study or trial • Budget and time allocated to perform an economic evaluation should not determine selection of evidence.
Measure of health outcome
• Methodological choices include either DALYs averted or QALYs gained • Full and transparent description of method used to calculate the chosen outcome measure 5. Costs
• Estimates should reflect the resource use and unit costs/prices that may be expected if the intervention is rolled out to the population defined in the decision problem • Costs not incurred in study settings but likely if intervention is rolled out should be captured in the analysis • Cost all resource implications relevant to the decision problem, including donated inputs and out of pocket inputs from individuals • Analysis should include estimation of changes in costs estimates due to economies (or diseconomies) of scale 6. Time horizon and discount rate
Lifetime time horizon should be used in first instance.
• A shorter time horizon may be used where shown that all relevant costs and effects are captured.
• 3% annual discount rate for costs and effects should be used in the analysis, with additional analyses exploring differing discount rates • Additional analysis should explore an annual discount rate that reflects the rate for government borrowings • Where the time horizon is> 30 years, the impact of lower discount rates should be explored in a sensitivity analysis 7. Non-health effects and costs outside health budget (perspective)
• Analysis should reflect direct health costs and health outcomes • A disaggregated societal perspective should be used to capture relevant non-health effects and costs that fall outside the health budget, to be included in additional analysis; the mechanism of inclusion will depend on the decision problem and context. • Where external funding or individual OOP payments substitute for costs that would otherwise fall on a health budget, these costs should be included in the analysis; the impact of excluding these should be explored in sensitivity analyses 8. Heterogeneity
Heterogeneity should be explored in population subgroups, where subgroup formation should be informed by:
• Relevant effect of the intervention differs in different populations • Characteristics of different populations that may influence the absolute health effects • Characteristics that influence direct costs of provision or other associated costs across the constituency Subgroup analysis should always be determined by:
• The evidence base regarding differences in relative effect, baseline risk or other characteristics • Whether the differences have an important influences on costs and effects
Uncertainty
The economic evaluation should explore:
• Uncertainty in the structure of the analysis • Uncertainty due to source of parameters • Uncertainty due to precision of parameters 10. Constraints
• Budget impact analysis should estimate the implications of implementing the intervention on various budgets • Budget impact analysis should reflect the decision problem and the constituency in which the intervention will be used.
Equity considerations
There are various mechanisms available for assessing equity implications of an intervention.
• The method chosen should be appropriate to the decision problem and justifiable to the decision maker • Equity implications should be considered at all stages of the evaluation, including design, analysis and reporting
